PF 6650833

Drug Profile

PF 6650833

Alternative Names: PF-06650833; PF-6650833

Latest Information Update: 16 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis
  • Phase I Lupus vulgaris

Most Recent Events

  • 13 Dec 2017 Interim pharmacokinetics and adverse events data from phase I trials in Healthy volunteers presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/AHRP-2017)
  • 01 Dec 2017 Pfizer completes a phase I trial in Rheumatoid arthritis (In volunteers) in Belgium (NCT03308110)
  • 11 Sep 2017 Phase-I clinical trials in Rheumatoid arthritis (In volunteers) in Belgium (PO) (NCT03308110)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top